1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > 20s Proteasome Inhibitors -Pipeline Insights, 2016

20s Proteasome Inhibitors -Pipeline Insights, 2016

  • November 2016
  • -
  • Delve Insight
  • -
  • 60 pages


DelveInsight’s, “20s Proteasome Inhibitors-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the 20s Proteasome Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for 20s Proteasome Inhibitors. DelveInsight’s Report also assesses the 20s Proteasome Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitive pipeline landscape of 20s Proteasome Inhibitors
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the 20s Proteasome Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for 20s Proteasome Inhibitors and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

20s Proteasome Inhibitors -Pipeline Insights, 2016

- 20s Proteasome Inhibitors Overview
- 20s Proteasome Inhibitors Disease Associated
- 20s Proteasome Inhibitors Pipeline Therapeutics
- 20s Proteasome Inhibitors Therapeutics under Development by Companies
- 20s Proteasome Inhibitors Filed and Phase III Products
- Comparative Analysis
- 20s Proteasome Inhibitors Phase II Products
- Comparative Analysis
- 20s Proteasome Inhibitors Phase I and IND Filed Products
- Comparative Analysis
- 20s Proteasome Inhibitors Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- 20s Proteasome Inhibitors - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- 20s Proteasome Inhibitors - Discontinued Products
- 20s Proteasome Inhibitors - Dormant Products
- Companies Involved in Therapeutics Development for 20s Proteasome Inhibitors
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for 20s Proteasome Inhibitors by Therapy Area, 2016
- Number of Products under Development for 20s Proteasome Inhibitors, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- 20s Proteasome Inhibitors Assessment by Monotherapy Products
- 20s Proteasome Inhibitors Assessment by Combination Products
- 20s Proteasome Inhibitors Assessment by Route of Administration
- 20s Proteasome Inhibitors Assessment by Stage and Route of Administration
- 20s Proteasome Inhibitors Assessment by Molecule Type
- 20s Proteasome Inhibitors Assessment by Stage and Molecule Type
- 20s Proteasome Inhibitors Therapeutics - Discontinued Products
- 20s Proteasome Inhibitors Therapeutics - Dormant Products
- Products under Development by Companies, 2016

List of Figures

- Number of Products under Development for 20s Proteasome Inhibitors by Therapy Area, 2016
- Number of Products under Development for 20s Proteasome Inhibitors, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- 20s Proteasome Inhibitors Assessment by Monotherapy Products
- 20s Proteasome Inhibitors Assessment by Combination Products
- 20s Proteasome Inhibitors Assessment by Route of Administration
- 20s Proteasome Inhibitors Assessment by Stage and Route of Administration
- 20s Proteasome Inhibitors Assessment by Molecule Type
- 20s Proteasome Inhibitors Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Related Market Segments :

Therapy
Targeted Therapy

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.